Flickdox CV 162.5 Tablet combines Cefpodoxime Proxetil 100mg and Clavulanic Acid 62.5mg, offering a potent broad-spectrum antibacterial effect against gram-positive and gram-negative organisms. The combination enhances bacterial eradication and prevents resistance, making it suitable for varied infections.
Cefpodoxime Proxetil, a third-generation cephalosporin, works by inhibiting bacterial cell wall synthesis, while Clavulanic Acid inhibits beta-lactamase enzymes, protecting cefpodoxime from degradation. Together, they provide enhanced efficacy against resistant bacterial strains.
Clinically, Flickdox CV 162.5 Tablet is indicated for respiratory tract infections, urinary tract infections, skin and soft tissue infections, and ENT infections. The tablet formulation ensures precise dosing, high bioavailability, and reliable therapeutic outcomes, making it ideal for hospital use, clinics, and outpatient prescriptions.
Regular administration helps in rapid resolution of infection, reduction of inflammation, prevention of recurrence, and improved patient recovery. Flickdox CV 162.5 Tablet is a trusted choice for effective management of bacterial infections in modern clinical practice.